hotspot -WSS

hotspot

author：fashion 2025-09-06 04:37:07 - browse：22

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The battle over 'scope creep' and who gets to be called 'doctor'

WSS

New lawsuit accuses health insurer Cigna of denying claims in bulk

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

STAT Report: Patient voices and perspectives

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Former reverend arrested for allegedly killing 8

New clues to why women have higher risk of autoimmune disorders

leisure time

hotspot

hotspot

Drug repurposing or repositioning? The language matters

Biogen walks away from Aduhelm, years after polarizing approval

State Dept. review finds Biden bears some blame for Afghanistan failures

Device maker Teleflex to acquire urology company for $600M

ChatGPT in medicine: STAT answers readers' burning questions

Rise in cancer among younger people worries and puzzles doctors

At least 13 dead in Texas as scorching temps continue

Humana’s losses in Medicare Advantage tank its stock

Guidelines to prevent youth baseball injuries need more muscle

Will the FTC rein in IQVIA's health data empire?

entertainment

Roche’s Alnylam deal shows drug firms interested in heart drugs

Rise in cancer among younger people worries and puzzles doctors

Investment in vaccine development is lagging, report finds

Search called off for baby washed away in Pennsylvania flash flood

New lawsuit accuses health insurer Cigna of denying claims in bulk

The battle over 'scope creep' and who gets to be called 'doctor'

knowledge

Wikipedia

leisure time

focus